Latest Information Update: 05 Jun 2001
At a glance
- Originator Shire Pharmaceuticals Group
- Class Antivirals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 05 Jun 2001 BioChem Pharma has been acquired by Shire Pharmaceuticals Group
- 31 May 2001 Discontinued-Preclinical for Hepatitis B in USA (Unknown route)
- 23 Apr 1999 New profile